Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mitiperstat (AZD4831) versus placebo in moderate to severe COPD
NL-OMON53515Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Feb 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in chronic obstructive pulmonary disease (COPD) comparing Mitiperstat with Placebo (2 arms). Primary endpoint: Time to first COPDCompEx event. Started Feb 2023; status: completed.
02
Drugs
mitiperstat
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NL-OMON53515.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53515.